Fig. 1
From: Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
Basic information for selected patients harboring concurrent alterations of EGFR sensitive mutations and MDM2 amplification. a CT and MRI scans of patients before and after the progression of the disease: new lesions in central nervous system of patient 1 were detected; the primary lesion of patient 2 was evaluated as progressive disease according to RECIST 1.1; b the carcinoembryonic antigen (CEA) change of patient 3 during the treatment process: CEA of patient 3 elevated drastically after approximately 2 months of gefitinib treatment